Ken Griffin Dyne Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$31.94 - $47.04 $239,550 - $352,800	7,500 Added 129.31%	13,300 $477,000
Q2 2024 Aug 14, 2024	SELL	$23.65 - $35.63 $690,580 - $1.04 Million	-29,200 Reduced 83.43%	5,800 $204,000
Q1 2024 May 15, 2024	BUY	$13.06 - $29.18 $150,190 - $335,570	11,500 Added 48.94%	35,000 $993,000
Q4 2023 Feb 14, 2024	BUY	$6.62 - $13.64 $117,174 - $241,428	17,700 Added 305.17%	23,500 $312,000
Q3 2023 Nov 14, 2023	BUY	$8.6 - $12.18 $16,340 - $23,142	1,900 Added 48.72%	5,800 $51,000
Q2 2023 Aug 14, 2023	BUY	$8.53 - $14.28 $29,854 - $49,980	3,500 Added 875.0%	3,900 $43,000
Q1 2023 May 15, 2023	SELL	$10.88 - $15.0 $41,344 - $57,000	-3,800 Reduced 90.48%	400 $4,000
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $39,354 - $57,960	4,200 New	4,200 $48,000

210

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.52B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.